Exploring the p53 tumor suppressor and its role in pediatric cancers
Pediatric adrenocortical carcinoma is considered a rare tumor, but incidence is particularly high in Brazilian children. Its concentrated prevalence is due to an inherited mutation in the p53 tumor suppressor. Our lab has a longstanding collaboration with colleagues in Brazil designed to understand the consequences of this mutation. We use genetic sequencing and experimental modeling to decipher the role of p53 in disease.
The research program in our laboratory focuses on the TP53 gene, particularly its regulators, the mechanisms underlying its activation, and the downstream targets that carry out its work as a tumor suppressor. Although we investigate p53 in the context of pediatric cancer generally, we have a specific interest in the role of p53 in adrenocortical carcinoma.
In the U.S., the incidence of adrenocortical carcinoma is 1 in 3 million – so rare that most pediatric oncologists can work their entire careers and never see a single case. When a case of adrenocortical carcinoma does occur, the treatment options for children are poor. In contrast to the US., the incidence of this cancer in Brazil is significantly higher and is attributed to an inherited, mutated form of the TP53 gene. For more than two decades our laboratory has been collaborating with colleagues in Brazil to better understand the structural and functional consequences of this p53 germline mutation.
Our laboratory conducts tissue culture studies where we reintroduce the mutated protein into cell lines to see whether it can control the cell cycle or influence cell death. We have developed a mouse model with the germline TP53 mutation as well as a novel PCR test for this hypomorphic mutant.
We have also been part of the Pediatric Cancer Genome Project at St. Jude, contributing 19 pediatric adrenocortical carcinoma samples matched with blood samples, and we developed a tumor bank as part of an international pediatric adrenocortical tumor registry (IPACTR). Collecting tumor samples from around the world, our laboratory conducts whole genome sequencing on these rare cancers. From those analyses, we determined that copy neutral loss of heterozygosity of specific genes and chromosomes may be driving the proliferation and survival of the adrenal tumors we are investigating.
In addition, our laboratory has generated mouse models that have mutations of both p53 and a gene called XAF1. The presence of both mutations underlies the significantly increased risk of adrenocortical carcinoma and other tumors in Brazilian carriers. We are currently exploring the underlying biology of this mutation combination to understand disease mechanism and improve risk prediction.
Dr. Gerard P. Zambetti is a pioneer in the field of p53 research. He is a longstanding member of the St. Jude faculty, directing a research lab that creates impact around the world. Dr. Zambetti currently serves as the Vice President and Director of Academic Programs in Biomedical Sciences, and the Associate Director of Education and Training for the Comprehensive Cancer Center at St. Jude. He is instrumental in expanding the global reach of St. Jude’s research efforts and is committed to inspiring the next generation of scientists with his thoughtful mentorship and engagement.
Committed team of researchers working on an international stage to understand the biology of p53 and pediatric adrenocortical carcinoma